BioCryst Pharmaceuticals, Inc. (BCRX) is a Biotechnology company in the Healthcare sector, currently trading at $9.67. It has a SharesGrow Score of 80/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BCRX = $60.02 (+520.7% from the current price, the stock appears undervalued). Analyst consensus target is BCRX = $16 (+65.5% upside).
Valuation: BCRX trades at a trailing Price-to-Earnings (P/E) of 7.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.
Financials: revenue is $875M, +50.8%/yr average growth. Net income is $264M, growing at +155.3%/yr. Net profit margin is 30.2% (strong). Gross margin is 97.8% (+0.8 pp trend).
Balance sheet: total debt is $477M with negative equity of -$119M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 2.06 (strong liquidity). Debt-to-assets is 92.8%. Total assets: $514M.
Analyst outlook: 25 / 29 analysts rate BCRX as buy (86%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 75/100 (Pass), Moat 66/100 (Partial), Future 94/100 (Pass), Income 100/100 (Pass).
